Ann: Quarterly Report & Appendix 4C, page-8

I am back in BDA this week after holding few months ago... IMO the most undervalued play in the medical cannabis space. EV<3mill, growing revenues from their current skincare and supplement range, recently signed a distribution agreement for maternal supplements.

Re MM, Phase I clinical trial designed for their flagship medicinal cannabis product/delivery system and they have already begun formulating a non-pharmaceutical cannabis skincare range for local and international markets (due for release in 2018).

Speculation of-course, but when/if cannabis importation licence is granted I expect the stock to move in a big way. The company's "exclusive relationship with Linnea gives it global access to a standardised GMP-approved cannabis extract", which is essential for  licencing a product in Aus (as in many other markets).  

In the meantime, still way undervalued IMO based on the their current growing suite of consumer products and I will continue to add at these levels.

Cheers and GLTA holders!